AGN won’t fail because it’s in a drug class that has always passed phase 2 studies and they have already showed efficacy on a smaller scale that inhibiting calcium influx protects the brain. NYR is well on its way because that mechanism of action is proven and AGN will pass with flying colours just like the previous drugs in the same drug class.
If you actually did any research into this space NYR based on previous clinical trials in humans will be a success. This 20 million market cap doesn’t reflect anything but things will change very quickly
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.18M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.0¢ | $114.5K | 576.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 78460 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 60000 | 2 |
View Market Depth
| Last trade - 15.59pm 16/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |